A Type II variation application seeking the approval of ciltacabtagene autoleucel in adult patients with relapsed and lenalidomide-refractory multiple myeloma has been submitted to the European Medicines Agency.
Recent Content
- Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact
- Bilateral Exudative Retinal Detachments and Panuveitis in a Patient with Multiple Myeloma
- FDA Lifts Partial Clinical Hold on Phase 1 Trial of MT-0169 in Multiple Myeloma, Hodgkin Lymphoma
- Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis
- Starving multiple myeloma cells via CDK7 inhibition
- Semistructured Patient Interviews Identify Facilitators of MM Treatment Initiation, Continuation
- Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma
- Severe laryngeal edema after CAR-T cell treatment in a patient with multiple myeloma: A case report
- Re-expansion of vertebral compression fractures in patients with multiple myeloma with percutaneous vertebroplasty using spinejack implants: a preliminary and retrospective study
- Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis